CD30‐positive lymphoproliferative disorders—An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre
- 9 March 2023
- journal article
- review article
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 64 (2) , 194-203
Abstract
The CD30‐postive lymphoproliferative disorders, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, account for up to 30% of all cutaneous T‐cell lymphomas (CTCLs) and are the second most common form of CTCLs after mycosis fungoides. Both conditions differ in their clinical presentations; however, they share the expression of the CD30 antigen as a common immunophenotypic hallmark. There is a wide spectrum of management options depending on factors such as extent of disease, staging and treatment tolerability. This Clinical Practice Statement is reflective of the current clinical practice in Australia.Keywords
This publication has 71 references indexed in Scilit:
- EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*Blood, 2011
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood, 2011
- Bone marrow examination has limited value in the staging of patients with an anaplastic large cell lymphoma first presenting in the skin. Retrospective analysis of 107 patientsBritish Journal of Dermatology, 2008
- Medium-dose UVA1 therapy of lymphomatoid papulosisJournal of the American Academy of Dermatology, 2005
- Management of multifocal primary cutaneous CD30+ anaplastic large cell lymphomaJournal of the American Academy of Dermatology, 2004
- Cd30+ cutaneous lymphoproliferative disorders: The stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphomaJournal of the American Academy of Dermatology, 2003
- Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disordersJournal of the American Academy of Dermatology, 1996
- Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disordersJournal of the American Academy of Dermatology, 1993
- Topical carmustine (BCNU) for cutaneous T cell lymphoma: A 15-year experience in 143 patientsJournal of the American Academy of Dermatology, 1990
- The clinicopathologic spectrum of lymphomatoid papulosis: Study of 31 casesJournal of the American Academy of Dermatology, 1983